CytoSorbents Corp

Invention:	Cytokine adsorber
Trademark:	CytoSorb®
Patents:	TBA
NASDAQ:	CTSO

​The invention:

• CytoSorbents' lead product, CytoSorb, is an extracorporeal cytokine adsorber, which is approved in the European Union and distributed in over 58 countries worldwide. It is designed to reduce cytokine storm or cytokine release syndrome in common critical illnesses that can lead to massive inflammation, organ failure, and patient death.
• CytoSorb is also used during and after cardiac surgery to remove antithrombotic drugs and inflammatory mediators that can lead to postoperative complications, including severe bleeding and multiple organ failure.
• In these diseases, the risk of death can be extremely high, and there are few, if any, effective treatments. CytoSorb has been used cumulatively in more than 122,000 human treatments.
• The company's purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption.
• CytoSorbents’ technology addresses a major unmet medical need, with applications in multiple critical illnesses, organ transplant, cancer, autoimmune disease, and others.

Performance Advantage:

• Incumbent technologies or products in this space include a range of medical therapies such as corticosteroids, immunosuppressants, and anti-inflammatory drugs, as well as supportive care techniques in intensive care settings. CytoSorb's uniqueness lies in its approach to directly adsorb excessive cytokines and other inflammatory mediators from the blood, offering a potentially more direct and efficient way to manage severe inflammatory responses compared to traditional pharmacological interventions.

Intellectual Property:

• The company's blood purification technologies are protected by many issued U.S. and international patents and registered trademarks, as well as multiple patent applications pending, including ECOS-300CY, CytoSorb-XL, HemoDefend-RBC, HemoDefend-BGA, VetResQ, K+ontrol, DrugSorb-ATR, DrugSorb, and ContrastSorb.
• CytoSorbents has also received FDA Emergency Use Authorization in the United States for use in adult critically ill COVID-19 patients with impending or confirmed respiratory failure.
• The DrugSorb-ATR antithrombotic removal system, based on the same polymer technology as CytoSorb, has received two FDA Breakthrough Device Designations, one for the removal of ticagrelor and another for the removal of direct oral anticoagulants apixaban and rivaroxaban, during urgent cardiothoracic surgery.

Addressable market:

• The addressable market for CytoSorb for the treatment of sepsis in the United States and European Union is estimated to be approximately $6 billion to $8 billion​​. This figure underscores the significant market potential for CytoSorb in these regions, particularly in the context of its application in critical care and cardiac surgery.

Upside:
As at the time of writing (January 2024), CytoSorbents corp has a market cap (USD$50m) that is small relative to the size of the company's addressable market. 



Sources:

CytoSorbent Corp Annual Report, 2023